Blog | HemaCare

HemaCare’s Super Donors to the Rescue!

Mar 17, 2021 10:25:00 AM / by Nancy Andon, MSc posted in Gene Therapy, Cell Therapy Manufacturing, GMP Cellular Therapeutics


New webinar highlights the benefits of “dedicated donor pools” - the latest offering from HemaCare to accelerate successful cell therapy research and commercialization

HemaCare, through Charles River Labs, recently hosted an educational webinar focused on their latest cell and gene therapy-related service.

HemaCare will now be working with clients to establish “dedicated donor” pools. The purpose of this new program is to establish and maintain a pool of reliable, recallable donors with client-determined physiological and/or demographic characteristics that match specific client research projects and programs.

Read More

FDA Grants New Therapy for Sickle Cell Treatment

May 5, 2020 10:05:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Gene Therapy, Cell Therapy, Stem Cells


A newly developed single-treatment approach, uses autologous gene therapy and CD34 stem cells to improve erythrocyte function in SSD patients.

Sickle cell disease (SSD) refers to a group of inherited erythrocyte disorders. Hemoglobin in people with SSD becomes defective leading to abnormal shaping of erythrocytes. The defective hemoglobin form, hemoglobin S, replaces the normal hemoglobin A. The abnormally crescent or sickle-shaped erythrocytes cause a number of illnesses associated with the clogging of vessels, poor oxygen flow to organs, and associated damage.

Read More

X-ALD Patients Hope to See Results With Cell-Based Gene Therapy

Mar 31, 2020 10:06:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Gene Therapy, Bone Marrow, Cell Therapy, CNS/Neurodegeneration


As Phase 3 clinical trials begin for Lenti-D as a treatment for patients with X-ALD, the drug also shows promise for treating a range of neurodegenerative diseases.

X‐linked adrenoleukodystrophy (X‐ALD) is a peroxisomal disorder resulting from a mutation in the human ATP-binding cassette, sub-family D, member 1 gene (ABCD1). The ABCD1 gene codes for the adrenoleukodystrophy protein (ALDP) needed for very-long-chain fatty acids (VLCFAs) to enter peroxisomes for degradation. When this process is disrupted, the VLCFAs accumulate in various tissues of the body, including the brain. VLCFA accumulation and demyelination of brain white matter lead to the severe neurological symptoms seen with X-ALD.

Read More

HemaCare Publication Highlights Role of Cell Therapy Starting Materials

Jan 7, 2020 10:04:00 AM / by Nancy Andon, MSc posted in Gene Therapy, Cell Therapy


HemaCare Corporation’s latest publication in BioPharm International [1] sheds light on a topic that has been preoccupying some of the best minds in cell therapy research; the need to ensure a reliable supply of top-notch starting materials for up-and-coming cell and gene therapies.

Unlike traditional medical treatments, the raw materials for these therapies cannot simply be manufactured. Instead, the supply of starting materials relies on a steady influx of voluntary donors willing to take the time to undertake a fairly complex screening process and donate peripheral blood or bone marrow for altruistic reasons. Nor is a reliable donor pool the only criteria necessary to supplying materials for a successful cellular therapeutic. Starting material quality and consistency ultimately determine the reliable efficacy of the final product.

Read More

The Changing Landscape of Clinical Approval

Aug 27, 2019 10:04:00 AM / by Nancy Andon, MSc posted in Gene Therapy, Cell Therapy, Drug Discovery


HemaCare is pleased to announce the publication of our latest article [1] in the journal International Clinical Trials (ICT). The paper, entitled “The Landscape of Clinical Approval” describes how changes in the clinical drug approval process are impacting starting material suppliers, and what suppliers are doing to meet increased demands.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts